10XBIO
10xBio is a biotechnology company that focuses on new uses for existing therapies and technologies. This strategy allows us to build on existing safety profiles and leverage known mechanisms of action, resulting in a streamlined development and regulatory process. Their most advanced asset, 10XB101, is a pharmaceutical product that addresses unmet needs in dermatologic medicine.
10XBIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2012-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.10xbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.66 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Current Employees Featured
Official Site Inspections
http://www.10xbio.com Semrush global rank: 5.29 M Semrush visits lastest month: 1.56 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "10xBio"
10xBio | Innovations in Body Contouring
Aug 16, 2023 John Dobak, M.D., is the Chairman of 10xBio. He has spent the last 25 years developing novel medical technologies. Most recently he served as the CEO of DermTech, the leader in genomics and precision medicine for …See details»
10xBio - Crunchbase Company Profile & Funding
10xBio is a biotechnology company that focuses on new uses for existing therapies and …See details»
10xbio - Overview, News & Similar companies | ZoomInfo.com
Who is 10xbio. We are a biotechnology company that focuses on new uses for existing …See details»
10xBio Company Profile - Office Locations, Competitors, Revenue …
10xBio is a biopharmaceutical company that develops drugs based on established active …See details»
10XBIO, LLC Company Profile | La Jolla, CA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for 10XBIO, …See details»
Overview & Company Highlights - 10xBio
10xBio LLC-Confidential. 10XB101 Kybella* PR ≥ 1 85% 80% CR ≥ 1 77% 80% PR ≥ 2 77% …See details»
10xBio - VentureRadar
10xBio Follow Following Location: USA. Founded in 2015. Develops innovative biotechnology …See details»
10xBio - Updates, News, Events, Signals & Triggers - Crunchbase
Mar 9, 2024 Organization. 10xBio . Connect to CRM . Save . Summary. Financials. People. …See details»
10xBio - Products, Competitors, Financials, Employees, …
10xBio is a biotechnology company that specializes in identifying new applications for existing …See details»
10xBio - Contacts, Employees, Board Members, Advisors & Alumni …
Organization. 10xBio . Connect to CRM . Save . Summary. Financials. People. Technology. …See details»
10xBio Completes Series B Financing | 10xBio
10xBio Completes Series B Financing. August 23, 2021. SAN DIEGO (August 23, 2021) – …See details»
10xBio's Phase 2b Trial Suggests Improved Submental Fat …
Mar 15, 2024 10xBio, LLC, a firm specializing in biotechnology, has unveiled early clinical trial …See details»
10xBio Announces the Completion of Enrollment In Phase 2b …
Aug 16, 2023 The drug, 10XB101, is a proprietary formulation of polidocanol, which is …See details»
10xBio Announces Data from Interim Analysis of Phase 2b Clinical …
SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that …See details»
PRESS RELEASES - 10xBio
SAN DIEGO (August 12, 2021) – 10xBio, LLC, a privately-held biotechnology company, …See details»
10xBio Announces the Completion of Enrollment In Phase 2b …
SAN DIEGO, Aug. 16, 2023 /PRNewswire/ — 10xBio, LLC, a biotechnology company that …See details»
10xBio's Novel Submental Body Contouring Drug & Upcoming
Sep 11, 2023 10xBio has announced the completed enrollment for a repeat treatment study …See details»
10xBio Announces the Completion of Phase 1B Clinical Trial of …
SAN DIEGO (May 6, 2019) – 10xBio, LLC, a privately-held biotechnology company, …See details»
10xBio Announces Data from Interim Analysis of Phase 2b Clinical …
Mar 12, 2024 The findings were presented in a late-breaking research abstract at the 2024 …See details»
10xBio Announces the Completion of Phase 2 Clinical Trial of …
SAN DIEGO (August 3, 2021) – 10xBio, LLC, a privately-held biotechnology company, …See details»